PG Pharmaceuticals: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
PG Pharmaceuticals
Largest movements
- Tangible fixed assets -€57,228
down €57,228 (-5.2%), from €1.1m to €1.0m
of which Land and buildings: -€52,032
- Debts after one year -€120,532
down €120,532 (-7.0%), from €1.7m to €1.6m
- Profit (loss) carried forward +€81,699
up €81,699 (+46.6%), from -€175,417 to -€93,718
- Other debts -€23,028
down €23,028 (-42.6%), from €54,034 to €31,006
- Tax, wage and social debts +€22,678
up €22,678 (+102.5%), from €22,122 to €44,800
of which Remuneration and social security: +€16,800
- Gross operating margin +€218,254
up €218,254, from -€14,971 to €203,283
- Financial charges +€17,228
up €17,228 (+47.8%), from €36,021 to €53,249
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,914,938 | €1,863,378 | -€51,560 | -2.7% |
| Fixed assets | 21/28 | €1,900,576 | €1,843,348 | -€57,228 | -3.0% |
| Tangible fixed assets | 22/27 | €1,101,257 | €1,044,029 | -€57,228 | -5.2% |
| Land and buildings | 22 | €1,060,823 | €1,008,791 | -€52,032 | -4.9% |
| Plant, machinery and equipment | 23 | €3,920 | €5,606 | +€1,686 | +43.0% |
| Furniture and vehicles | 24 | €10,296 | €6,036 | -€4,260 | -41.4% |
| Other tangible fixed assets | 26 | €26,218 | €23,597 | -€2,622 | -10.0% |
| Financial fixed assets | 28 | €799,319 | €799,319 | = | 0.0% |
| Current assets | 29/58 | €14,362 | €20,030 | +€5,668 | +39.5% |
| Amounts receivable within one year | 40/41 | €1,458 | €8,273 | +€6,815 | +467.3% |
| Trade receivables | 40 | - | €7,894 | +€7,894 | |
| Other amounts receivable | 41 | €1,458 | €380 | -€1,079 | -74.0% |
| Cash at bank and in hand | 54/58 | €1,575 | €1,054 | -€520 | -33.0% |
| Deferred charges and accrued income | 490/1 | €11,329 | €10,702 | -€627 | -5.5% |
| Total equity and liabilities | 10/49 | €1,914,938 | €1,863,378 | -€51,560 | -2.7% |
| Equity | 10/15 | -€15,417 | €66,282 | +€81,699 | |
| Contributions | 10/11 | €160,000 | €160,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€175,417 | -€93,718 | +€81,699 | +46.6% |
| Amounts payable | 17/49 | €1,930,356 | €1,797,096 | -€133,260 | -6.9% |
| Amounts payable after more than one year | 17 | €1,717,697 | €1,597,165 | -€120,532 | -7.0% |
| Financial debts | 170/4 | €1,717,697 | €1,597,165 | -€120,532 | -7.0% |
| Amounts payable within one year | 42/48 | €203,554 | €197,672 | -€5,882 | -2.9% |
| Current portion of amounts payable after more than one year | 42 | €120,532 | €120,532 | = | 0.0% |
| Trade debts | 44 | €6,865 | €1,334 | -€5,532 | -80.6% |
| Suppliers | 440/4 | €6,865 | €1,334 | -€5,532 | -80.6% |
| Taxes, remuneration and social security | 45 | €22,122 | €44,800 | +€22,678 | +102.5% |
| Taxes | 450/3 | €3,098 | €8,976 | +€5,878 | +189.7% |
| Remuneration and social security | 454/9 | €19,024 | €35,824 | +€16,800 | +88.3% |
| Other amounts payable | 47/48 | €54,034 | €31,006 | -€23,028 | -42.6% |
| Accrued charges and deferred income | 492/3 | €9,105 | €2,259 | -€6,846 | -75.2% |
| Non-recurring operating income | 76A | €2,242 | €323 | -€1,919 | -85.6% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €61,147 | €61,194 | +€48 | +0.1% |
| Other operating charges | 640/8 | €5,284 | €6,923 | +€1,639 | +31.0% |
| Non-recurring operating charges | 66A | €3,436 | - | -€3,436 | |
| Gross operating margin | 9900 | -€14,971 | €203,283 | +€218,254 | |
| Operating profit (loss) | 9901 | -€84,839 | €135,166 | +€220,004 | |
| Financial income | 75/76B | €34 | €3 | -€31 | -91.7% |
| Recurring financial income | 75 | €34 | €3 | -€31 | -91.7% |
| Financial charges | 65/66B | €36,021 | €53,249 | +€17,228 | +47.8% |
| Recurring financial charges | 65 | €36,021 | €53,249 | +€17,228 | +47.8% |
| Profit (loss) for the period before taxes | 9903 | -€120,826 | €81,919 | +€202,745 | |
| Income taxes | 67/77 | €682 | €220 | -€461 | -67.7% |
| Profit (loss) for the period | 9904 | -€121,507 | €81,699 | +€203,206 | |
| Profit (loss) for the period to be appropriated | 9905 | -€121,507 | €81,699 | +€203,206 |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 5 October 2026 via checked.be.